Neumora Therapeutics Details Significant Executive Compensation Changes, Including Option Repricing and Large New Grants

summarizeSummary

Neumora Therapeutics disclosed a significant repricing of executive and director stock options to $0.72 per share and issued substantial new option grants totaling 6 million shares to its top executives, alongside details of a former CEO's severance.

check_boxKey Events

• Executive and Director Stock Option Repricing

  In May 2025, outstanding stock options for named executive officers and non-employee directors with exercise prices higher than $0.72 per share were repriced to $0.72 per share, a significant reduction from initial prices (e.g., $1.69).

• Substantial New Executive Option Grants

  In February 2025, the company granted 2 million options to the CEO, 3 million to the President, and 1 million to the Chief Operating and Development Officer, totaling 6 million shares with an exercise price of $1.69 per share. This represents approximately 3.28% potential dilution.

• Former CEO Severance Package

  Henry O. Gosebruch, former President and CEO, received a severance package in February 2025, including 12 months of continued base salary, his 2025 target bonus, and up to 18 months of healthcare coverage.

• Shareholder Meeting Proposals

  The annual meeting on May 27, 2026, will include votes on the election of three Class III directors, ratification of Ernst & Young LLP as auditor, a non-binding advisory vote on executive compensation, and an advisory vote on the frequency of future 'say on pay' votes.

auto_awesomeAnalysis

This definitive proxy statement reveals several material executive compensation decisions. Most notably, the company repriced outstanding stock options for its named executive officers (NEOs) and non-employee directors in May 2025, lowering the exercise price to $0.72 per share for options previously set at $1.69 or higher. This repricing is a significant negative for shareholders as it effectively re-grants options at a more favorable strike price, increasing the potential value for executives at the expense of shareholder dilution. Additionally, the company granted substantial new stock options to its CEO (2 million shares), President (3 million shares), and Chief Operating and Development Officer (1 million shares) in February 2025, totaling 6 million shares. These grants represent approximately 3.28% potential dilution based on current outstanding shares. The filing also details the severance package for the former President and CEO, Henry O. Gosebruch, which included 12 months of continued base salary and a target bonus for 2025. While the company adopted positive governance measures like a clawback policy and an insider trading policy prohibiting hedging, the significant option repricing and large new grants are the dominant, negative market-moving factors.